Denali Therapeutics Inc. (DNLI) financial statements (2023 and earlier)

Company profile

Business Address 161 OYSTER POINT BLVD.
SOUTH SAN FRANCISCO, CA 94080
State of Incorp. DE
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments8651,470415464
Cash and cash equivalents2935077977
Short-term investments572963336387
Receivables16 1
Prepaid expense   1
Other undisclosed current assets31201514
Total current assets:8971,496430481
Noncurrent Assets
Operating lease, right-of-use asset313334
Property, plant and equipment39414725
Long-term investments and receivables4253340148
Long-term investments4253340148
Other noncurrent assets12238
Total noncurrent assets:507109123181
TOTAL ASSETS:1,4041,604553662
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities51320
Accounts payable5132
Accrued liabilities   9
Employee-related liabilities   10
Deferred revenue282019
Deferred rent credit   1
Contract with customer, liability11
Other liabilities5347240
Other undisclosed current liabilities2924  
Total current liabilities:378724533
Noncurrent Liabilities
Long-term debt and lease obligation596469 
Operating lease, liability596469
Liabilities, other than long-term debt4244482
Deferred revenue32344
Contract with customer, liability57
Deferred rent credit   25
Other liabilities0100
Other undisclosed noncurrent liabilities1294  
Total noncurrent liabilities:6438211382
Total liabilities:442454158115
Stockholders' equity
Stockholders' equity attributable to parent9621,151395547
Common stock2211
Additional paid in capital1,6081,504819774
Accumulated other comprehensive income (loss)(2)(0)0(1)
Accumulated deficit(645)(354)(426)(228)
Total stockholders' equity:9621,151395547
TOTAL LIABILITIES AND EQUITY:1,4041,604553662

Income statement (P&L) ($ in millions)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
Revenues4933627129
Revenue from related parties4307  
Gross profit:4933627129
Operating expenses(344)(273)(240)(176)
Operating income (loss):(296)63(213)(46)
Nonoperating income591510
Investment income, nonoperating(9)(0)53
Income (loss) from continuing operations before income taxes:(291)72(198)(36)
Income tax benefit110 
Net income (loss):(291)73(198)(36)
Other undisclosed net loss attributable to parent (2)  
Net income (loss) available to common stockholders, diluted:(291)71(198)(36)

Comprehensive Income ($ in millions)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
Net income (loss):(291)73(198)(36)
Comprehensive income (loss):(291)73(198)(36)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(2)(2)1(0)
Comprehensive income (loss), net of tax, attributable to parent:(293)71(197)(37)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: